About STADA Arzneimittel

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. Segments The company operates through two segments, Generics and Branded Products. The company provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcers/refluxes; Diclofenac for pain/inflammation; and Enalapril for high blood pressure. The company also offers APO-Go, a Parkinson’s medicine; Aqualor for rhinitis/sore throat; Grippostad for cold; Snup for rhinitis; and Vitaprost for prostate disease treatment. Customers The company serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy cooperatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. Sales Network As of March 1, 2016, the company had four market regions, including Germany, Central Europe, Commonwealth of Independent States (CIS)/Eastern Europe and Asia/Pacific, and the Middle East and North Africa with various sales companies. The sales focus was on the market regions, such as Germany, Central Europe and CIS/Eastern Europe. Strategy The key elements of the company’s strategy include growth based on a multi-pillar strategy; and strategic success factors for the utilization of existing growth opportunities. Research and Development Costs The research and development costs amounted to € 65.0 million in the year ended December 31, 2015. History The company was founded in 1895.